Fraud charges filed against diagnostic company
This article was originally published in Clinica
The US Securities and Exchange Commission has brought fraud charges against the now defunct company, Novatek International, reports Barron's, a US business weekly. The company is alleged to have issued false press releases two years ago, claiming it had revenues of $400 million in non-existent transactions, concerning sales of HIV blood test kits in South America.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.